XBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
660.6K
-18.1%
806.9K
0
0
-100.0%
589.9K
Cost of Revenue
0
0
0
0
0
Gross Profit
660.6K
-18.1%
806.9K
0
0
-100.0%
589.9K
Operating Expenses
1.6M
+24.7%
1.3M
-5.8%
1.4M
-11.6%
1.6M
+19.6%
1.3M
R&D
552.0K
-16.5%
661.4K
-14.5%
773.4K
+2.2%
756.5K
+15.2%
656.6K
SG&A
1.1M
+66.8%
647.6K
+5.1%
615.9K
-24.4%
815.2K
+23.9%
657.8K
Operating Income
-971690
-93.5%
-502117
+63.9%
-1389323
+11.6%
-1571691
-117.0%
-724412
EBITDA
-971690
-93.5%
-502117
+63.9%
-1389323
+11.6%
-1571691
-117.0%
-724412
Net Income
-929695
-103.7%
-456382
+21.2%
-579076
-13.6%
-509940
+26.0%
-688703
EPS (Basic)
$-0.41
-105.0%
$-0.20
+25.9%
$-0.27
+18.2%
$-0.33
+26.7%
$-0.45
EPS (Diluted)
$-0.41
-105.0%
$-0.20
+25.9%
$-0.27
+18.2%
$-0.33
+26.7%
$-0.45
Shares (Diluted)
2.3M
+0.1%
2.3M
+5.1%
2.2M
+41.4%
1.5M
+0.0%
1.5M
Xenetic Biosciences (XBIO) โ€” Financials